Adriaan Hart de Ruijter
Managing Director @ Cascara Ventures
Brussels, Belgium
Adriaan Hart de Ruijter is a Series A investor at Cascara Ventures in Brussels focused on Medical and Health Care. Adriaan Hart de Ruijter has over twenty-seven years of experience in the life science industry. After a career in pharmaceuticals he founded MSOURCE, the contract research organization in 1994, which he sold to TÜV SÜD in 2008. Since then he ventured into medical data, imaging, oncology and several therapeutic areas through partnerships and venturecapital, building new companies and realizing exits. Adriaan Hart de Ruijter is on the board of many life science companies. His particular interests are to collaborate with excellent teams, working on promising scientific breakthroughs and creating meaningful improvements to healthcare.Adriaan Hart de Ruijter holds an MD from Leiden University and an MBA from Erasmus University in the Netherlands. He is well known for his passion for the sea, regatta sailing and diving.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Adriaan Hart de Ruijter invests in
Stages Adriaan Hart de Ruijter invests in
Countries Adriaan Hart de Ruijter invests in
Investment Focus
Industry
- Medical 3 (30%)
- Health Care 3 (30%)
- Wearables 2 (20%)
- Biotechnology 2 (20%)
- Medical Device 2 (20%)
Stage
- Series A 4 (40%)
- Seed 3 (30%)
- Series B 2 (20%)
- Series C 1 (10%)
Country
- Germany 4 (40%)
- Finland 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Surgify
|
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). | $7.9M / Series A / May 27, 2025 | |
|
Surgify
|
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). | $1.1M / Seed / Oct 25, 2017 | |
microDimensions
|
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. | Series A / Jun 16, 2016 | |
Xbird
|
xbird is a provider of software solutions in the healthcare sector, founded in Berlin in 2015. The company uses artificial intelligence to personalize therapies for better results. Especially in diabetes therapy, the algorithms developed by xbird can record the behavior and lifestyle of patients using smartphones and other wearables. In this way,as part of holistic care, health risks can be identified and prevented and long-term treatment can be optimized. | Seed | |
Preventicus
|
Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. It generates data conclusive to a degree previously only obtainable by physicians. Preventicus’ software applications are certified medical devices with an accuracy verified in clinical studies. Its primary product is a classI medical device. Preventicus is the creator of Preventicus Heartbeats, a smart screening solution that identifies atrial fibrillation for stroke prevention, based on technologies that are present in a standard smartphone or smartwatch.Preventicus was founded in 2014 by Thomas Hübner. It is based in Jena, Germany. | Series A | |
Fiagon
|
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. | Series C | |
|
microDimensions
|
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. | Seed | |
|
Fiagon
|
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. | Series B | |
SurgicEye
|
SurgicEye designs intra-operative imaging and instrument navigation solutions for surgical procedures. It offers a navigated radio-guided surgery based on the handheld 3-D freehand SPECT imaging technology called the declipse SPECT open surgery, an intraoperative 3D imaging system for invasive sentinel lymph node biopsy called the declipse SPECTLaparascopy, and a mobile SPECT imaging solution with a high resolution on a small footprint called the declipse SPECT imaging probe. The company also advises clients on medical device development, requirement engineering and software specification for medical devices, software development for medical devices, testing of software for medical devices, and support in the design and conduction of clinical studies.Dr. Jörg Traub founded SurgicEye in 2008, with its headquarters in Munich in Germany. | Series B | |
Meidrix Biomedicals
|
Meidrix Biomedicals is a medical biotechnology company that specializes in medical devices for cartilage repair. Meidrix Biomedicals also offers regenerative and biological medical products. Meidrix Biomedicals was founded in 2009 and was headquartered in Bayern, Germany. | Series A |
Co-Investors
About Cascara Ventures
Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics,healthcare services, diagnostics and cell therapy.
Cascara Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Adriaan Hart de Ruijter
Managing Director
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adriaan Hart de Ruijter invest in?
Adriaan Hart de Ruijter invests primarily in Medical, Health Care and Wearables startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Adriaan Hart de Ruijter last invest?
The most recent investment recorded for Adriaan Hart de Ruijter closed in May 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
